Drug and Therapeutics Bulletin 2003;41:91-96; doi:10.1136/dtb.2003.411291
Copyright © 2003 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Management of bronchiectasis

Around 1 in 1,000 adults in the UK has bronchiectasis, a potential outcome of various underlying lung diseases.1,2 It results from a 'vicious circle' of recurrent infection, inflammation, excessive mucus production, reduced mucociliary clearance, and dilatation and destruction of bronchi.1–4 Associated damage to blood vessels can lead to haemoptysis, which is usually slight, but may be severe.1 Bronchiectasis may be limited to one area (localised) or be more widespread (generalised). It can reduce lung function and quality of life, and may lead to respiratory failure and premature death.1 Here we review the management of patients with bronchiectasis.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2003 BMJ Publishing Group Ltd.